vinblastine/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to the noscapine analog 9-aminonoscapine, pharmaceutical compositions incorporating 9-aminonoscapine analog, and methods of using the compound and compositions to treat cancers, including drug resistant cancers. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to the noscapine analog 9-aminonoscapine, pharmaceutical compositions incorporating 9-aminonoscapine analog, and methods of using the compound and compositions to treat cancers, including drug resistant cancers. BACKGROUND OF THE

This application is the U.S. national phase of International Application No. PCT/CN2007/003624 filed 17 Dec. 2007, which designated the U.S., and claims priority to Chinese application No. 200710036923.2, filed 29 Jan. 2007 the entire contents of each of which are hereby incorporated by

BACKGROUND OF THE INVENTION The indole-indoline alkaloids, the most important of which can be represented by the compound of formula I ##STR1## wherein R.sub.2 is acetoxy or hydroxy; and R is formyl or methyl; include vinblastine and vincristine, which are anti-tumor agents widely used in the

BACKGROUND OF THE INVENTION The indole-indoline alkaloids, the most important of which can be represented by the compound of formula I ##STR1## wherein R.sub.2 is acetoxy or hydroxy; and R is formyl or methyl include vinblastine and vincristine, which are anti-tumor agents widely used in the

FIELD OF THE INVENTION The present invention relates generally to the in vivo detection and measurement of the dose critical levels of certain anti-cancer drugs in blood, serum and other biological fluids, more specifically to the detection of such drugs using a probe DNA and still more specifically

BACKGROUND OF THE INVENTION In 1996 cancer of the prostate gland was expected to be diagnosed in 317,000 men in the U.S. and 42,000 American males die from this disease (Garnick, M. B. (1994). The Dilemmas of Prostate Cancer. Scientific American, April:72-81). Thus, prostate cancer is the most

FIELD OF INVENTION The present invention relates to the field of medicine. More particularly, the invention relates to compounds, pharmaceutical compositions and uses thereof for the treatment of cancers. BACKGROUND OF INVENTION Cancer refers to more than one hundred clinically distinct forms of the

FIELD OF INVENTION The present invention relates to the field of medicine. More particularly, the invention relates to compounds, pharmaceutical compositions and uses thereof for the treatment of cancers. BACKGROUND OF INVENTION Cancer refers to more than one hundred clinically distinct forms of the

TECHNICAL FIELD The present invention is related generally to the use of antineoplastic vinca alkaloids as antitumour agents. More particularly, the present invention is related to providing use for a derivative of vinblastine, anhydrovinblastine (hereinafter AHVB), as an antineoplastic agent with

BACKGROUND ART The vinca alkaloids constitute a family of indole-indoline dimeric natural product compounds that continue to have a remarkable impact on anticancer drug discovery and treatment [Neuss et al., In The Alkaloids; Brossi, A., Suffness, M., Eds.; Academic: San Diego, Calif., 1990; Vol.

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is a U.S. National Stage entry under 35 U.S.C. .sctn. 371 of International Application No. PCT/CN2014/000192 filed on Mar. 3, 2014, designating the United States of America and published in Chinese on Oct. 23, 2014, which in turn claims

SUMMARY OF THE INVENTION In accordance with this invention it has been discovered that compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are in a cis relationship and taken together form --CH.sub.2 --(CH.sub.2).sub.n --CH.sub.2 ; or R.sub.1 and R.sub.2 taken together with their attached

SUMMARY OF THE INVENTION In accordance with this invention it has been discovered that compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are in a cis relationship and taken together form --CH.sub.2 --(CH.sub.2).sub.n --CH.sub.2 ; or R.sub.1 and R.sub.2 taken together with their attached

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage application of PCT/JP2006/316353, filed Aug. 22, 2006, which claims priority from Japanese application JP 2005-240424, filed Aug. 22, 2005. TECHNICAL FIELD The present invention relates to novel combination anticancer